These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 35075935)

  • 21. Investigation of von Willebrand factor multimer abnormalities before and after aortic valve replacement using the Hydragel-5 assay.
    Hamiko M; Gerdes L; Silaschi M; Seidel H; Westhofen P; Kruppenbacher J; Hertfelder HJ; Oldenburg J; Bakhtiary F; Velten M; Oezkur M; Duerr GD
    Thromb Res; 2024 Jul; 241():109094. PubMed ID: 38991494
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High Molecular Weight von Willebrand Factor Multimer Loss and Bleeding in Patients with Short-Term Mechanical Circulatory Support Devices: A Case Series.
    Goldfarb M; Czer LS; Lam LD; Moriguchi J; Arabia FA; Volod O
    J Extra Corpor Technol; 2018 Jun; 50(2):77-82. PubMed ID: 29921985
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Loss of von Willebrand factor high-molecular-weight multimers at acute phase is associated with detectable anti-ADAMTS13 IgG and neurological symptoms in acquired thrombotic thrombocytopenic purpura.
    Béranger N; Benghezal S; Savigny S; Capdenat S; Joly BS; Coppo P; Stepanian A; Veyradier A
    Thromb Res; 2019 Sep; 181():29-35. PubMed ID: 31330376
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased thrombin generation and platelet activation are associated with deficiency in high molecular weight multimers of von Willebrand factor in patients with moderate-to-severe aortic stenosis.
    Natorska J; Bykowska K; Hlawaty M; Marek G; Sadowski J; Undas A
    Heart; 2011 Dec; 97(24):2023-8. PubMed ID: 21561895
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Reliable von Willebrand factor: ristocetin cofactor enzyme-linked immunosorbent assay to differentiate between type 1 and type 2 von Willebrand disease.
    Vanhoorelbeke K; Cauwenberghs N; Vandecasteele G; Vauterin S; Deckmyn H
    Semin Thromb Hemost; 2002 Apr; 28(2):161-6. PubMed ID: 11992239
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Non-surgical bleeding in patients with ventricular assist devices could be explained by acquired von Willebrand disease.
    Geisen U; Heilmann C; Beyersdorf F; Benk C; Berchtold-Herz M; Schlensak C; Budde U; Zieger B
    Eur J Cardiothorac Surg; 2008 Apr; 33(4):679-84. PubMed ID: 18282712
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acquired Von Willebrand syndrome in patients on long-term support with HeartMate II.
    Heilmann C; Trummer G; Beyersdorf F; Brehm K; Berchtold-Herz M; Schelling J; Geisen U; Zieger B
    Eur J Cardiothorac Surg; 2017 Mar; 51(3):587-590. PubMed ID: 28082469
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Extracorporeal membrane oxygenation induces short-term loss of high-molecular-weight von Willebrand factor multimers.
    Tauber H; Ott H; Streif W; Weigel G; Loacker L; Fritz J; Heinz A; Velik-Salchner C
    Anesth Analg; 2015 Apr; 120(4):730-6. PubMed ID: 25565317
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of two von Willebrand factor collagen-binding assays with different binding affinities for low, medium, and high multimers of von Willebrand factor.
    Neugebauer BM; Goy C; Budek I; Seitz R
    Semin Thromb Hemost; 2002 Apr; 28(2):139-48. PubMed ID: 11992237
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acquired von Willebrand syndrome in patients with an axial flow left ventricular assist device.
    Meyer AL; Malehsa D; Bara C; Budde U; Slaughter MS; Haverich A; Strueber M
    Circ Heart Fail; 2010 Nov; 3(6):675-81. PubMed ID: 20739614
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gain-of-function GPIb ELISA assay for VWF activity in the Zimmerman Program for the Molecular and Clinical Biology of VWD.
    Flood VH; Gill JC; Morateck PA; Christopherson PA; Friedman KD; Haberichter SL; Hoffmann RG; Montgomery RR
    Blood; 2011 Feb; 117(6):e67-74. PubMed ID: 21148813
    [TBL] [Abstract][Full Text] [Related]  

  • 32. von Willebrand factor disruption and continuous-flow circulatory devices.
    Proudfoot AG; Davidson SJ; Strueber M
    J Heart Lung Transplant; 2017 Nov; 36(11):1155-1163. PubMed ID: 28756118
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acquired von Willebrand syndrome in paediatric patients during mechanical circulatory support.
    Kubicki R; Stiller B; Kroll J; Siepe M; Beyersdorf F; Benk C; Höhn R; Grohmann J; Fleck T; Zieger B
    Eur J Cardiothorac Surg; 2019 Jun; 55(6):1194-1201. PubMed ID: 30590475
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Decreased RPM reduces von Willebrand factor degradation with the EVAHEART LVAS: implications for device-specific LVAD management.
    Bartoli CR; Kang J; Motomura T
    J Card Surg; 2020 Jul; 35(7):1477-1483. PubMed ID: 32652785
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acquired type 2A von Willebrand syndrome caused by aortic valve disease corrects during valve surgery.
    Solomon C; Budde U; Schneppenheim S; Czaja E; Hagl C; Schoechl H; von Depka M; Rahe-Meyer N
    Br J Anaesth; 2011 Apr; 106(4):494-500. PubMed ID: 21278152
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reduced continuous-flow left ventricular assist device speed does not decrease von Willebrand factor degradation.
    Kang J; Zhang DM; Restle DJ; Kallel F; Acker MA; Atluri P; Bartoli CR
    J Thorac Cardiovasc Surg; 2016 Jun; 151(6):1747-1754.e1. PubMed ID: 26971377
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A mathematical model for assessing shear induced bleeding risk.
    Li Y; Wang H; Xi Y; Sun A; Wang L; Deng X; Chen Z; Fan Y
    Comput Methods Programs Biomed; 2023 Apr; 231():107390. PubMed ID: 36745955
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of Von Willebrand factor (VWF) activity VWF:Ac with VWF ristocetin cofactor activity VWF:RCo.
    Geisen U; Zieger B; Nakamura L; Weis A; Heinz J; Michiels JJ; Heilmann C
    Thromb Res; 2014 Aug; 134(2):246-50. PubMed ID: 24891215
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.
    Michiels JJ; van de Velde A; van Vliet HH; van der Planken M; Schroyens W; Berneman Z
    Semin Thromb Hemost; 2002 Apr; 28(2):111-32. PubMed ID: 11992235
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
    Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.